Quest Partners LLC reduced its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 7.1% during the 3rd quarter, ...

JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune ...

Blueprint Medicines' AYVAKIT leads its revenue growth, while its pipeline targets multiple cancers. Read why BPMC stock is a ...

JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune mast cells. In 2023, the FDA approved Blueprint Medicines’ Ayvakit ...

Blueprint Medicines (BPMC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on ...

At this time, I would like to welcome everyone to the Blueprint Medicines Third Quarter 2024 Financial Results Conference Call. [Operator Instructions] Thank you. Jenna Cohen, you may begin your ...

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Blueprint Medicines BPMC in the last three months. In the table below, you'll find a summary ...

Blueprint Medicines (NASDAQ:BPMC) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Blueprint Medicines Corp. (BPMC) on Wednesday reported a loss of $56.3 million in its third quarter. The Cambridge, Massachusetts-based company ...